Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crown

Showing results (71-80 of 202) with videos related to

Pageof 21
Sort By:
Oncoimmunology|December 7, 2017
Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesiclesVanesa G Martinez, Sadhbh O'Neill, Josephine Salimu, et al.
Cancer Metastasis Reviews|July 2, 2023
Carcinoma of unknown primary (CUP): an update for histopathologistsKatie Beauchamp, Bruce Moran, Timothy O'Brien, et al.
Molecular Cancer|March 25, 2014
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Cancer Treatment Reviews|December 3, 2014
p53 as a target for the treatment of cancerMichael J Duffy, Naoise C Synnott, Patricia M McGowan, et al.
Molecular Cancer|July 3, 2013
A gene expression profile indicative of early stage HER2 targeted therapy responseFiona O'Neill, Stephen F Madden, Martin Clynes, et al.
Cureus|November 17, 2017
Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?Lisa Prior, Marvin Lim, Cian Ward, et al.
Molecular Cancer|June 20, 2012
Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell linesFiona O'Neill, Stephen F Madden, Sinead T Aherne, et al.
Investigational New Drugs|October 19, 2012
EGFR and HER2 inhibition in pancreatic cancerNaomi Walsh, Susan Kennedy, AnneMarie Larkin, et al.
Cancers|August 29, 2024
Molecular Analysis of Salivary and Lacrimal Adenoid Cystic CarcinomaSarah Powell, Karina Kulakova, Katie Hanratty, et al.
Journal of Cancer|June 21, 2021
Hindsight: Review of Preclinical Disease Models for the Development of New Treatments for Uveal MelanomaCaoimhe Goldrick, Letizia Palanga, Bobby Tang, et al.
Pageof 21

Showing results (71-80 of 202) with videos related to

Sort By:
Pageof 21
Oncoimmunology|December 7, 2017
Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesiclesVanesa G Martinez, Sadhbh O'Neill, Josephine Salimu, et al.
Cancer Metastasis Reviews|July 2, 2023
Carcinoma of unknown primary (CUP): an update for histopathologistsKatie Beauchamp, Bruce Moran, Timothy O'Brien, et al.
Molecular Cancer|March 25, 2014
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Cancer Treatment Reviews|December 3, 2014
p53 as a target for the treatment of cancerMichael J Duffy, Naoise C Synnott, Patricia M McGowan, et al.
Molecular Cancer|July 3, 2013
A gene expression profile indicative of early stage HER2 targeted therapy responseFiona O'Neill, Stephen F Madden, Martin Clynes, et al.
Cureus|November 17, 2017
Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?Lisa Prior, Marvin Lim, Cian Ward, et al.
Molecular Cancer|June 20, 2012
Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell linesFiona O'Neill, Stephen F Madden, Sinead T Aherne, et al.
Investigational New Drugs|October 19, 2012
EGFR and HER2 inhibition in pancreatic cancerNaomi Walsh, Susan Kennedy, AnneMarie Larkin, et al.
Cancers|August 29, 2024
Molecular Analysis of Salivary and Lacrimal Adenoid Cystic CarcinomaSarah Powell, Karina Kulakova, Katie Hanratty, et al.
Journal of Cancer|June 21, 2021
Hindsight: Review of Preclinical Disease Models for the Development of New Treatments for Uveal MelanomaCaoimhe Goldrick, Letizia Palanga, Bobby Tang, et al.
Pageof 21